

STEMCELLS INC
Form 8-K
May 17, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

May 17, 2012

StemCells, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-19871

94-3078125

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

7707 Gateway Blvd, Suite 140, Newark,
California

94560

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

510.456.4000

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 8.01 Other Events.

On May 17, 2012, StemCells, Inc. (the "Company") issued a press release announcing the presentation of interim data from the Phase I/II clinical study of its HuCNS-SC cells (purified human neural stem cells) in patients with spinal cord injury. The data will be presented by Armin Curt, M.D., principal investigator for the study, on May 17, 2012, at the Interdependence 2012 Global SCI Conference, which is being held in Vancouver, British Columbia. A copy of this press release is attached hereto as Exhibit 99.1.

The interim data is from the first cohort of patients in the study, all of whom suffered a complete spinal cord injury in which there is no neurological function below the level of the injury. There were no abnormal clinical, electrophysiological or radiological responses to the cells, and all the patients were neurologically stable through the first four months following transplantation of the cells. Changes in sensitivity to touch were observed in two of the patients.

The data from multiple evaluations of the patients during this four month period have been reviewed by an independent Data Safety Monitoring Committee, which has recommended that the study advance to enrollment of patients with incomplete neurological injury. Enrollment is now underway and is open to patients in Europe, the United States and Canada with incomplete spinal cord injury.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99.1 Press Release, dated May 17, 2012, announcing interim data from the Company's clinical study of HuCNS-SC cells in patients with spinal cord injury.

Edgar Filing: STEMCELLS INC - Form 8-K

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

StemCells, Inc.

May 17, 2012

By: */s/ Kenneth Stratton*

Name: Kenneth Stratton

Title: General Counsel

Edgar Filing: STEMCELLS INC - Form 8-K

Top of the Form

Exhibit Index

Exhibit No.	Description
99.1	Press Release of StemCells, Inc., dated May 17, 2012